Evidence in the Wild

FDA Bayesian Review Checklist

Know the questions a skeptical FDA reviewer will probe — before you're in the room.

Get the Checklist — $49

Latest Articles

Apr

7 min read

The Substudies You Never Hear About: Why Most ComboMATCH Protocols Die Before They Reach a Patient

ComboMATCH is described as having opened with multiple treatment trials and more in development. The design paper lists the scientific rationale, the biomarker-matching infrastructure, and the cooperative group coordination. Press releases count the substudies that activated. The ECOG-ACRIN treatment trials page lists the ones currently open or closed to accrual.

Apr

7 min read

What Everyone Else Submitted to FDA on the Bayesian Guidance

The disagreements in the comment docket tell you where Bayesian regulatory science still hasn't settled.

Mar

6 min read

The Grammar No One Reads: How Platform Trials Standardize Statistical Design

If you look at a single ComboMATCH substudy on ClinicalTrials.gov, you see a clinical trial. Two-stage design, 30 patients, objective response rate. It looks like any Phase II study. If you look across substudies, you see something different. You see a system. I was a statistician on two SWOG